Q-omics provides the consensus-scored ZNF20 profile across patient tissues and cancer cell-line models. ZNF20 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ZNF20 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, ZNF20 RNA expression shows 19,009 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, KIRC, and UVM as cancer lineages where ZNF20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF20 survival associations across molecular data types. ZNF20 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF20 RNA expression–survival associations across cancer types. High ZNF20 expression shows unfavorable associations in KICH, UCS and LGG, but favorable associations in HNSC, BRCA and LAML. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for ZNF20 RNA expression.
This table summarizes ZNF20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF20 shows lower tumor expression in KIRC, KICH and THCA and higher tumor expression in LIHC, BRCA and CHOL. The KIRC box plot shows higher ZNF20 RNA expression in normal versus tumor tissue (log2 FC = −0.190, t-test p < 0.001).
This table shows molecular features associated with ZNF20 in patient tissues and cancer cell lines. In patient samples, ZNF20 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
